Do patients with chronic kidney disease get optimal cardiovascular risk reduction?

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 3, 2014, Pages 267-274

  Elliott, Mark K ^a   McCaughan, Jennifer A ^a   Fogarty, Damian G ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

cardiovascular disease; chronic kidney disease; nonclassical cardiovascular risk factors; risk reduction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATE BINDING AGENT; VITAMIN B GROUP;

ALBUMINURIA; ANEMIA; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BLEEDING TENDENCY; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; META ANALYSIS (TOPIC); MINERAL BONE DISEASE; MULTICENTER STUDY (TOPIC); OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL INACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RESISTANT HYPERTENSION; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION; SEVERE RENAL IMPAIRMENT; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; UREMIA; CARDIOVASCULAR DISEASES; HEALTH CARE DELIVERY; LIFESTYLE; MORTALITY; PREDICTIVE VALUE; PREVENTIVE HEALTH SERVICE; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIFE STYLE; PREDICTIVE VALUE OF TESTS; PREVENTIVE HEALTH SERVICES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 84898540049     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000444913.78536.b1     Document Type: Review

References (83)

1. Hajhosseiny R, Khavandi K, Goldsmith DJ. Cardiovascular disease in chronic kidney disease: untying the Gordian knot. Int J Clin Pract 2013; 67:14-31.
2. Perazella MA, Khan S. Increased mortality in chronic kidney disease: a call to action. Am J Med Sci 2006; 331:150-153.
3. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 Suppl.):S16-S23.
4. Parikh NI, Hwang SJ, Larson MG, et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med 2006; 166:1884-1891.
5. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161:1207-1216.
6. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57:327-335.
7. Van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341-1352.
8. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
9. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380:1662-1673.
10. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380:1649-1661.
11. Moody WE, Edwards NC, Chue CD, et al. Arterial disease in chronic kidney disease. Heart 2013; 99:365-372.
12. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
13. Perna AF, Ingrosso D, Violetti E, et al. Hyperhomocysteinemia in uremia - a red flag in a disrupted circuit. Semin Dial 2009; 22:351-356.
14. Swaminathan S, Shah SV. Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int 2011; 80:453-463.
15. Del Vecchio L, Locatelli F, Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis - clinical effects, potential treatment, and prevention. Semin Dial 2011; 24:56-64.
16. Horl WH Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301.
17. Eddington H, Kalra PA. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. J Ren Care 2010; 36 (Suppl. 1):61-67.
18. Murray AM, Seliger S, Lakshminarayan K, et al. Incidence of stroke before and after dialysis initiation in older patients. J Am Soc Nephrol 2013; 24:1166-1173.
19. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS. 2 Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl. 5):v1-v52.
20. Scottish Intercollegiate Guidelines Network. Clinical guidelines: risk estimation and the prevention of cardiovascular disease. Edinburgh: SIGN; 2007.
21. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635-1701.
22. National Institute for Health and Care Excellence. MI: Secondary Prevention. CG48. London: National Institute for Health and Care Excellence; 2013.
23. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
24. ODonnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a casecontrol study. Lancet 2010; 376:112-123.
25. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004; CD003041.
26. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
27. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1:CD004816.
28. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
29. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343:d4169.
30. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
31. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-1860.
32. Flather MD, Yusuf S, Kber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575-1581.
33. Bangalore S, Steg G, Deedwania P, et al. b-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308:1340-1349.
34. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356:2388-2398.
35. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17:530-540.
36. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296:1377-1384.
37. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006; 70:2021-2030.
38. Ninomiya T, Perkovic V, Turnbull F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013; 347:f5680.
39. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373:1009-1015.
40. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53:860-866.
41. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:251-262.
42. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:263-275.
43. Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 2013; 34:1807-1817.
44. Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; 2:CD008834.
45. Lacson E, Lazarus JM. The association between blood pressure and mortality in ESRD - not different from the general population? Semin Dial 2007; 20:510-517.
46. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008; 155:791-805.
47. Rakugi H,Ogihara T,Umemoto S, et al.Combination therapy for hypertension in patients withCKD: a subanalysis of theCombination Therapy ofHypertension to Prevent Cardiovascular Events trial. Hypertens Res 2013; 36:947-958.
48. Rahman M, Ford CE, Cutler JA, et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012; 7:989-1002.
49. Iseki K, Arima H, Kohagura K, et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant 2013; 28:1579-1589.
50. Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int 2011; 80:978-985.
51. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
52. Fraser SD, Roderick PJ, McIntyre NJ, et al. Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Fam Pract 2013; 14:88.
53. Hill CJ, Cardwell CR, Patterson CC, et al. Chronic kidney disease and diabetes in the National Health Service: a cross-sectional survey of the UK National Diabetes Audit. Diabet Med 2014; 31:448-454; doi: 10.1111/ dme.12312. [Epub ahead of print]
54. Kuznik A, Mardekian J, Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010. BMC Nephrol 2013; 14:132.
55. Foster MC, Rawlings AM, Marrett E, et al. Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States. Am Heart J 2013; 166:150-156.
56. Sim JJ, Bhandari SK, Shi J, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc 2013; 88:1099-1107.
57. Tanner RM, Calhoun DA, Bell EK, et al. Prevalence of apparent treatmentresistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013; 8:1583-1590.
58. Ito H, Mifune M, Abe M, et al. Hypertension resistant to antihypertensive agents commonly occurs with the progression of diabetic nephropathy in Japanese patients with type 2 diabetes mellitus: a prospective observational study. BMC Nephrol 2012; 13:48. doi: 10.1186/1471-2369-13-48.
59. Lithovius R, Harjutsalo V, Forsblom C, et al. Antihypertensive treatment and resistant hypertension in patients with type 1 diabetes by stages of diabetic nephropathy. Diabetes Care 2013; 37:709-717. doi: 10.2337/dc13-2023.
60. De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013; 61:2461-2467.
61. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192.
62. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248.
63. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-1407.
64. Baigent C, Landray MJ, Reith C. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192. doi: 10.1016/S0140-6736(11)60739-3.
65. Gremmel T, Muller M, Steiner S, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant 2013; 28:2116-2122.
66. Lin TH, Lai WT, Hsin HT, et al. Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. PLoS One 2013; 8:e71917.
67. Nauta ST, van Domburg RT, Nuis RJ, et al. Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease: evolution from the prethrombolysis to the percutaneous coronary intervention era. Kidney Int 2013; 84:353-358.
68. Voller H, Gitt A, Jannowitz C, et al. Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting. Eur J Prev Cardiol 2014; doi:10.1177/ 2047487313482285. [Epub ahead of print]
69. McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast materialinduced nephropathy: causal or coincident phenomenon? Radiology 2013; 267:106-118. doi: 10.1148/radiol.12121823.
70. Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58:1152-1161.
71. Bae EH, Lim SY, Cho KH, et al. GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry. Am J Kidney Dis 2012; 59:795-802.
72. Cardinal H, Madore F. [Are cardioprotective drugs underused after a myocardial infarction in patients who suffer from chronic kidney disease?]. Nephrol Ther 2010; 6:162-170.
73. Zachariah D, Brown R, Kanagala P, et al. The impact of age and chronic kidney disease on secondary prevention post primary percutaneous coronary intervention (PPCI). QJM 2013; 107:185-192.
74. Qin X, Huo Y, Langman CB, et al. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2011; 6:482-488.
75. Jardine MJ, Kang A, Zoungas S, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ 2012; 344:e3533.
76. Pan Y, Guo LL, Cai LL, et al. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr 2012; 108:400-407.
77. Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013; 10:e1001436.
78. Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78:578-589.
79. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339.
80. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482-2494.
81. Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011; 57:422-431.
82. Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators.Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7:487-493.
83. Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013; 62:771-778.